Top Markets
Coin of the day
Vaxart, Inc. Vaxart, Inc.

Vaxart, Inc.

VXRT
Rang in aandelen #20724
Vaxart, Inc. operates as a biotechnology firm currently in the clinical... Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Aandeelprijs
$0.5106
Marktkapitalisatie
$123.59M
Verandering (1 dag)
-1.81%
Verandering (1 jaar)
45.89%
Land
US
Handel Vaxart, Inc. (VXRT)

Categorie

P/S-ratio voor Vaxart, Inc. (VXRT)
P/S-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Vaxart, Inc. is de huidige P/S-ratio (TTM) 0. Eind 2026 had het bedrijf een P/S-ratio van 0.
P/S-ratiohistoriek voor Vaxart, Inc. van 2026 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH